Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent
MT Newswires Live
Sep 29
Acadia Pharmaceuticals (ACAD) said late Monday the US Patent and Trademark Office issued a notice of allowance for a patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome.
The company said the patent, if issued, is expected to provide US protection for trofinetide through March 28, 2041, including six months of pediatric exclusivity, extending protection by nearly five years.
Trofinetide is marketed in the US as "Daybue" and "Daybue Stix" for the treatment of Rett syndrome in adults and children age 2 and older. The drug is also covered by a method-of-use patent that expires in July 2036, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.